Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Artemether,Lumefantrine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novartis and Medicines for Malaria Venture Report Positive Data for Malaria in Babies
Details : Coartem® (artemether-lumefantrine) a novel formulation which is being developed forthe treatment of babies weighing less than 5kg with malaria.
Product Name : Coartem
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 23, 2024
Lead Product(s) : Artemether,Lumefantrine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ganaplacide,Lumefantrine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Medicines for Malaria Venture
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KAF156 (Ganaplacide), belongs to a novel class of antimalarial molecules (imidazolopiperazines), has an effect on parasite internal protein secretory pathway. A key strength of the drug is its potential to both treat and prevent malaria, including resist...
Product Name : KAF156
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 23, 2022
Lead Product(s) : Ganaplacide,Lumefantrine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Medicines for Malaria Venture
Deal Size : Inapplicable
Deal Type : Inapplicable